<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04362644</url>
  </required_header>
  <id_info>
    <org_study_id>R20-010</org_study_id>
    <nct_id>NCT04362644</nct_id>
  </id_info>
  <brief_title>Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see if imaging with [18F]FDG and [18F]DPA-714 using positron
      emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis
      in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help
      physicians and researchers better understand how best to treat patients with IPF in the
      future.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlate quantitative PET measures of lung inflammation with [F-18]FDG and [F-18]DPA-714 to pulmonary function tests.</measure>
    <time_frame>screening to 48 hours post 2nd imaging visit.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>PET/CT using PET ligands [18F]FDG and [18F]DPA-714</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714</intervention_name>
    <description>Study participants will undergo PET/CT with the glucose analogue [F-18]FDG and the TSPO ligand [F-18]DPA-714 in two separate imaging sessions.</description>
    <arm_group_label>PET/CT using PET ligands [18F]FDG and [18F]DPA-714</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 40-85 years old.

          2. A diagnosis of IPF that fulfills ATS/ERS 2018 consensus criteria within 5 years.

          3. Ability and willingness to give informed consent and adhere to study requirements.

          4. Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC)
             &gt;0.70.

          5. High or mixed affinity binder for TSPO ligands based on genotyping for SNP rs6971.

        Exclusion Criteria:

          1. Acute exacerbation of IPF within &lt;30 days

          2. Diagnosis of Diabetes Mellitus (Type 1 or Type 2).

          3. Diagnoses of current infection by clinical or microbial assessments.

          4. Treatment for &gt;14 days within the preceding month with &gt;20 mg. prednisone (or
             equivalent) or any treatment during the last month with a cellular immunosuppressant.

          5. Subjects with prior radiation therapy to the thorax.

          6. Women who are pregnant, or who are breastfeeding. IPF is a disease of older adults,
             and male predominant, so this will not be a frequent consideration.

          7. Severe cardiovascular disease, defined as any of the following within the preceding 12
             weeks: acute myocardial infarction or unstable angina, a coronary revascularization
             procedure, or stroke.

          8. Subjects with known liver disease.

          9. Diagnosis of any active cancer with the exception of basal cell carcinoma of skin.

         10. Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.

         11. Active cigarette smoking or vaping
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan McConathy, MD, PhD</last_name>
    <phone>205-996-7115</phone>
    <email>jmcconathy@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>April Riddle, BSRT</last_name>
    <phone>205-934-6504</phone>
    <email>ariddle@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>April Riddle, BSRT</last_name>
      <phone>205-934-6504</phone>
      <email>ariddle@uabmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jonathan E McConathy</investigator_full_name>
    <investigator_title>M.D. P.h.D., Director for the Division Molecular Imaging and Therapeutics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

